Largan Precision Co., Ltd. logo

Largan Precision Co., Ltd. (3008)

Market Closed
12 Jun, 05:30
TWSE TWSE
NT$
4,020. 00
-145
-3.4814%
NT$
294.3B Market Cap
24.31 P/E Ratio
56% Div Yield
3.22M Volume
0 Eps
NT$ 4,165
Previous Close
Add Transaction
Day Range
4,020 4,355
Year Range
2,020 4,355
Want to track 3008 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

3008 closed today lower at NT$4,020, a decrease of -3.4814% from yesterday's close, completing a monthly increase of 10.7438% or NT$390. Over the past 12 months, 3008 stock gained 58.2677%.
3008 pays dividends to its shareholders, with the most recent payment made on Apr 16, 2026. The next estimated payment will be in In 4 months on Oct 16, 2026 for a total of NT$52.
The last earnings report, released on Apr 09, 2026, missed the consensus estimates by -39.73%. On average, the company has fell short of earnings expectations by -27.6733%, based on the last three reports.
Largan Precision Co., Ltd. has completed 8 stock splits, with the recent split occurring on Aug 10, 2009.
The company's stock is traded on one exchange.

3008 Chart

People also search for

Taiwan Semiconductor Manufacturing Company Limited
NT$ 2,310
+2.6667%
Hon Hai Precision Industry Co., Ltd.
NT$ 260.5
+0.7737%
Delta Electronics Inc.
NT$ 2,215
+2.5463%
MediaTek Inc.
NT$ 4,180
+2.3256%
Quanta Computer Inc.
NT$ 372
+0.5405%

Largan Precision Co., Ltd. (3008) FAQ

What is the stock price today?

The current price is NT$4,020.00.

On which exchange is it traded?

Largan Precision Co., Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 3008.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 56%.

What is its market cap?

As of today, the market cap is 294.3B.

Has Largan Precision Co., Ltd. ever had a stock split?

Largan Precision Co., Ltd. had 8 splits and the recent split was on Aug 10, 2009.

Largan Precision Co., Ltd. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Mr. En-Ping Lin CEO
TWSE Exchange
TW0003008009 ISIN
TW Country
- Employees
19 Mar 2026 Last Dividend
10 Aug 2009 Last Split
- IPO Date

Overview

SCI Pharmtech, Inc. is a multifaceted company that focuses on the research and development, manufacture, and sale of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. Founded in 1987 and headquartered in Taoyuan City, Taiwan, SCI Pharmtech, Inc. has established its presence not only domestically but also on a global scale. The company is recognized for its wide range of high-quality pharmaceutical products that cater to the needs of the pharmaceutical industry. Additionally, SCI Pharmtech, Inc. offers custom manufacturing services, indicating a flexible approach to meeting the diverse needs of its clientele. The company enjoys a broad international market, extending its sales network to Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, the Netherlands, and beyond.

Products and Services

  • Active Pharmaceutical Ingredients (APIs): SCI Pharmtech, Inc. produces a variety of APIs including, but not limited to, Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. These ingredients are essential for the development and production of effective medications.
  • Intermediate Products: The company's intermediate portfolio encompasses a variety of chemical compounds such as Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and many others. These intermediates play crucial roles in the synthesis of APIs and the development of new drugs.
  • Custom Manufacturing Services: Apart from its extensive catalog of APIs and intermediates, SCI Pharmtech, Inc. provides tailor-made manufacturing solutions. This service caters to clients with specific requirements, allowing for the custom production of unique chemical compounds or pharmaceutical ingredients.

Contact Information

Address: No.11, Jingke Road, Taichung, Taiwan, 40852
Phone: 886 4 3600 2345